OmniComm Systems' Awarded Four Clinical Trials from US Biotechnology Company
OmniComm Systems
announced that its TrialMaster suite of applications and IVRS technology has been chosen by a biotechnology company to manage their clinical data management and randomization needs for four key clinical trials. All four studies, leveraging OmniComm's Software-as-a-Service (SaaS) rapid-deployment model, will be put into production by the end of May.
OmniComm has also recently become a Society for Clinical Data Management CCDM partner, an achievement that is bestowed upon companies that are committed to quality clinical data management and Certified Clinical Data Manager (CCDM) credentialing. Qualifying companies must have at least 10 certified CCDMs or 25% of CDMs must have achieved certification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
